论文部分内容阅读
PenwestPharmaceuticals公司的一日1次的奥昔布宁（oxybutynin）口服控释制剂（商品名CystrinCR）首次在芬兰上市治疗尿失禁。由于目前可采用的疗法皆需一日给药2～4次，因此本品的上市是这类病人的一大福音。本品是1997年底在芬兰获得许可用于这一适应证的。控释奥昔市宁的释
A once-a-day oral oxybutynin controlled-release formulation (CystrinCR) by Penwest Pharmaceuticals Inc. is on sale in Finland for the first time to treat urinary incontinence. As currently available therapies are required to be administered one to four times a day, so the listing of this product is a major blessing for such patients. This product is licensed by the end of 1997 in Finland for this indication. Release controlled release oxine Ning